Clinical Decision Support for Respiratory Infections
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new tool, the iCPR system, to assist nurses in deciding when to prescribe antibiotics for acute respiratory infections, such as coughs and sore throats. The goal is to ensure antibiotics are used only when necessary, based on the tool's guidance. The trial involves two groups: one using the new tool and one continuing with standard care. Nurses who regularly see patients and use electronic health records can participate. Patients eligible for this trial are those visiting participating clinics with a cough or sore throat complaint. As an unphased trial, this study allows patients to contribute to innovative healthcare solutions that could improve antibiotic use.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It focuses on evaluating a tool for prescribing antibiotics for respiratory infections.
What prior data suggests that this clinical prediction tool is safe for use in guiding antibiotic prescriptions?
Research has shown that the iCPR system, a decision-support tool for doctors, has been tested in regular healthcare settings. Although it did not significantly reduce antibiotic prescriptions for upper respiratory infections, studies found no evidence of harm or side effects from its use. Thus, the iCPR system is considered safe and well-tolerated for guiding treatment decisions for acute respiratory infections (ARIs).12345
Why are researchers excited about this trial?
Researchers are excited about the iCPR system because it's designed to enhance clinical decision-making for respiratory infections. Unlike standard care, which often relies on generalized protocols, the iCPR system provides personalized, real-time support by guiding healthcare providers through specific workflows and risk assessments. This approach allows for more tailored care, potentially improving patient outcomes and treatment efficiency. The combination of online and in-person training ensures that clinic personnel are well-equipped to use the system effectively, which could lead to better management of respiratory infections.
What evidence suggests that the iCPR system is effective for guiding antibiotic prescriptions for acute respiratory infections?
Research has shown that tools like the iCPR system, which participants in this trial may receive, can assist doctors and nurses in making better decisions about antibiotic use for respiratory infections. These tools guide healthcare providers on when to prescribe antibiotics. However, one study found that the iCPR tool did not significantly reduce antibiotic prescriptions in primary care settings. While these systems have the potential to aid decision-making, their actual impact on changing prescription habits can vary. This underscores the need for further research to determine how best to use these tools in different healthcare settings.36789
Who Is on the Research Team?
Devin Mann, MD
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
This trial is for patients aged 3-70 with sore throat and 18-70 with cough, seen at participating clinics. Nurses prescribing treatment must work at least half-time, be licensed, use the clinic's EHR system regularly, and see a sufficient number of patients to maintain skills.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Training and Implementation
Clinic personnel receive online and in-person training on the iCPR tool, followed by implementation of the intervention
Evaluation
Evaluation of the iCPR tool's effectiveness in reducing antibiotic prescriptions and its adoption by nurses
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- iCPR system
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator